New Pill Doubles Survival Time for Pancreatic Cancer Patients
A groundbreaking pill targeting mutations in 90% of pancreatic cancer patients has approximately doubled survival time in clinical trials, offering new hope for one of medicine's toughest challenges. After decades of failed attempts, researchers have finally cracked a target once considered "undruggable."